Skip to main content
Gan & Lee Pharmaceuticals. logo

Gan & Lee Pharmaceuticals. — Investor Relations & Filings

Ticker · 603087 ISIN · CNE100003ZH1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 874 across all filing types
Latest filing 2026-04-22 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 603087

About Gan & Lee Pharmaceuticals.

https://www.ganlee.com/

Gan & Lee Pharmaceuticals is a biopharmaceutical company specializing in the research, development, production, and commercialization of insulin analogs and medical devices. The company focuses on diabetes care, offering a comprehensive portfolio that includes insulin glargine, insulin lispro, and insulin aspart, alongside delivery systems such as reusable and disposable insulin pens. Beyond its core expertise in metabolic disorders, the firm is expanding its research pipeline into oncology, cardiovascular diseases, and autoimmune conditions. Utilizing advanced recombinant DNA technology, the company maintains vertically integrated manufacturing capabilities to ensure high-quality therapeutic solutions. Its products are distributed across global markets, aiming to improve the quality of life for patients requiring long-term endocrine management.

Recent filings

Filing Released Lang Actions
2025年度会计师事务所履职情况的评估报告
Audit Report / Information Classification · 85% confidence The document is an evaluation report of the external auditor’s performance, qualifications, independence, quality control processes, and compliance related to the 2025 audit. It is a standalone audit‐related information document assessing the auditor’s履职 (performance) rather than the company’s full financial statements or an AGM presentation. This fits the definition of an Audit Report / Information filing (AR). FY 2025
2026-04-22 Chinese
股东会听取：2025年度独立董事述职报告-郑国钧（已离职）
Governance Information Classification · 85% confidence The document is titled “2025年度独立董事述职报告” and consists of the independent director’s annual performance and governance activities (board and committee attendance, internal control oversight, communication with auditors, etc.). It is not an earnings release, share transaction, capital notice, or annual report. It is a corporate governance disclosure about board structure, director duties, and governance processes, matching the definition of Governance Information (CGR).
2026-04-22 Chinese
信息披露管理办法（2026年4月）
Governance Information Classification · 85% confidence The document is a detailed internal “Information Disclosure Management Measures” manual for 甘李药业股份有限公司. It lays out the company’s rules, procedures, and governance practices around information disclosure, board and management responsibilities, and compliance. It is not a periodic financial report, earnings release, regulatory announcement, or investor presentation, but rather an internal governance document. This aligns with the “Governance Information” (CGR) category.
2026-04-22 Chinese
关于回购注销部分限制性股票通知债权人的公告
Transaction in Own Shares Classification · 92% confidence The document is an official announcement by 甘李药业股份有限公司 regarding the repurchase and cancellation (“回购注销”) of its own restricted shares and the resultant reduction in registered capital. This falls squarely under a company buying back its own shares. Therefore, it should be classified as a Transaction in Own Shares (POS).
2026-04-22 Chinese
审计委员会对2025年度会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 98% confidence The document is a formal report issued by the company’s Board Audit Committee on the external auditor’s (致同会计师事务所) performance and supervisory duties for the 2025 fiscal year. It describes audit firm qualifications, appointment procedures, audit scope, findings, and oversight activities – a standalone audit oversight report. It is not a full annual report or an announcement of publication, but a detailed audit information report. Therefore, it fits the Audit Report / Information category. FY 2025
2026-04-22 Chinese
2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 85% confidence The document is a detailed “专项报告” on the deposit, management and actual use of funds raised from the company’s 2020 IPO during the 2025 period, including fund balances, investment of idle funds, and supervisory agreements. It is not an annual or interim financial report, nor a simple publication notice, but rather a statutory disclosure on the use of raised capital. This fits the Capital/Financing Update category.
2026-04-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.